CA2169159C - Composition pharmaceutique renfermant un complexe medicament/.beta.-cyclodextrine en combinaison avec un couple acide-base - Google Patents

Composition pharmaceutique renfermant un complexe medicament/.beta.-cyclodextrine en combinaison avec un couple acide-base Download PDF

Info

Publication number
CA2169159C
CA2169159C CA002169159A CA2169159A CA2169159C CA 2169159 C CA2169159 C CA 2169159C CA 002169159 A CA002169159 A CA 002169159A CA 2169159 A CA2169159 A CA 2169159A CA 2169159 C CA2169159 C CA 2169159C
Authority
CA
Canada
Prior art keywords
acid
pharmaceutical composition
couple
cyclodextrin
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002169159A
Other languages
English (en)
Other versions
CA2169159A1 (fr
Inventor
Timothy James Grattan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CA2169159A1 publication Critical patent/CA2169159A1/fr
Application granted granted Critical
Publication of CA2169159C publication Critical patent/CA2169159C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pharmaceutique destinée à être administrée par voie orale sous la forme d'une solution aqueuse comportant un complexe médicament/ beta -cyclodextrine, et caractérisée en ce qu'elle comporte également un couple acide-base pharmaceutiquement acceptable, de préférence un couple acide-base effervescent, en une dose suffisante pour provoquer la dissolution du complexe médicament/ beta -cyclodextrine lorsqu'on mélange la composition avec de l'eau froide, de manière à former une solution ayant un pH acide ou neutre. Le couple acide-base est de préférence un couple effervescent renfermant de l'acide citrique et/ou tartrique ainsi que du carbonate et/ou bicarbonate de sodium, et les médicaments utilisés dans la composition sont notamment des anti-inflammatoires non stéroïdiens tels que l'ibuprofène, le naproxen et le cétoprofène.
CA002169159A 1993-08-10 1994-07-29 Composition pharmaceutique renfermant un complexe medicament/.beta.-cyclodextrine en combinaison avec un couple acide-base Expired - Fee Related CA2169159C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9316580.1 1993-08-10
GB939316580A GB9316580D0 (en) 1993-08-10 1993-08-10 Pharmaceutical composition
PCT/EP1994/002515 WO1995004528A2 (fr) 1993-08-10 1994-07-29 COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPLEXE MEDICAMENT/β-CYCLODEXTRINE EN COMBINAISON AVEC UN COUPLE ACIDE-BASE

Publications (2)

Publication Number Publication Date
CA2169159A1 CA2169159A1 (fr) 1995-02-16
CA2169159C true CA2169159C (fr) 2005-01-25

Family

ID=10740244

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002169159A Expired - Fee Related CA2169159C (fr) 1993-08-10 1994-07-29 Composition pharmaceutique renfermant un complexe medicament/.beta.-cyclodextrine en combinaison avec un couple acide-base

Country Status (9)

Country Link
EP (1) EP0720476A1 (fr)
JP (1) JPH09501421A (fr)
CN (1) CN1112180C (fr)
AU (1) AU688789B2 (fr)
CA (1) CA2169159C (fr)
GB (1) GB9316580D0 (fr)
TW (1) TW354256B (fr)
WO (1) WO1995004528A2 (fr)
ZA (1) ZA945930B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
ES2189682B1 (es) * 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
CZ295151B6 (cs) * 2004-02-20 2005-06-15 I. Q. A., A. S. Stabilní, chuťově přijatelné sirupy obsahující ibuprofen a způsob jejich přípravy
ATE486593T1 (de) 2006-03-16 2010-11-15 Novartis Ag Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
KR20160033796A (ko) 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US20120101159A1 (en) * 2009-04-27 2012-04-26 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Ibuprofen lysinate oral suspension
DK2253329T3 (en) * 2009-04-27 2017-01-16 Laboratorio De Aplicaciones Farm S A Oral ibuprofen lysinate suspension.
JP5853430B2 (ja) * 2010-06-21 2016-02-09 大正製薬株式会社 内服液剤
CN101987089B (zh) * 2010-11-10 2012-07-04 天大药业（珠海）有限公司 泡腾药物制剂
GB201021267D0 (en) 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
US9084721B2 (en) * 2012-06-28 2015-07-21 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US20140079796A1 (en) * 2012-09-18 2014-03-20 Mcneil-Ppc, Inc. Sustained Release Oral Dosage Forms Comprising Low Melting Propionic Acid Derivative Particles
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
CA1298290C (fr) * 1987-01-09 1992-03-31 Herand M. Markarian Complexes d'ibuprofene, compositions contenant ces complexes et procedes pour leur preparation
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
CH677606A5 (fr) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
DE3838431A1 (de) * 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5019663A (en) * 1989-04-03 1991-05-28 Mobil Oil Corp. Heat balanced paraffin upgrading with co-fed oxygenate
JPH02279631A (ja) * 1989-04-18 1990-11-15 Yamanouchi Pharmaceut Co Ltd 薬物のシクロデキストリン包接体及びその製造法
CA2009326C (fr) * 1989-05-09 1998-01-27 Lawrence J. Daher Solution pour granulation aqueuse et methode pour granulation de tablettes
CA2021548A1 (fr) * 1989-09-01 1991-03-02 Ronald Nash Duvall Compose medicinal effervescent a teneur reduite en sodium pour le soulagement des symptomes du rhume et des allergies
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE4027927A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Brausekomponente und verfahren zu ihrer herstellung
DE4038314A1 (de) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm Komplexe des aktiven enantiomers des ibuprofens mit cyclodextrin
JP2579251B2 (ja) * 1991-03-12 1997-02-05 ロシェ・コンシューマー・ヘルス・（ワールドワイド）・リミテッド 非発泡性イブプロフェン組成物

Also Published As

Publication number Publication date
WO1995004528A2 (fr) 1995-02-16
AU688789B2 (en) 1998-03-19
CN1112180C (zh) 2003-06-25
WO1995004528A3 (fr) 1995-03-16
CA2169159A1 (fr) 1995-02-16
ZA945930B (en) 1995-04-05
AU7609994A (en) 1995-02-28
EP0720476A1 (fr) 1996-07-10
CN1133006A (zh) 1996-10-09
GB9316580D0 (en) 1993-09-29
JPH09501421A (ja) 1997-02-10
TW354256B (en) 1999-03-11

Similar Documents

Publication Publication Date Title
US5866162A (en) Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US20200323776A1 (en) Diclofenac formulations and methods of use
CA2169159C (fr) Composition pharmaceutique renfermant un complexe medicament/.beta.-cyclodextrine en combinaison avec un couple acide-base
US5616621A (en) Taste masking liquids
US7078053B2 (en) Ibuprofen composition
JPH0753662B2 (ja) 薬剤学的製剤及びその製造方法
US5597583A (en) Pharmaceutical composition
TW505525B (en) Pharmaceutical compositions based on diclofenac
HU226895B1 (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide
WO1995007104A1 (fr) Complexes d'insertion de bêta-cyclodextrine et de flurbiprofene, cetoprofene, et naproxene

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140729